Literature DB >> 24417250

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome.

J Shen1, G L-H Wong, H L-Y Chan, H-Y Chan, D K-W Yeung, R S-M Chan, A M-L Chim, A W-H Chan, P C-L Choi, J Woo, W C-W Chu, V W-S Wong.   

Abstract

BACKGROUND: The rs738409 GG variant in patatin-like phospholipase 3 (PNPLA3) is associated with non-alcoholic fatty liver disease (NAFLD) and disease severity. However, it remains unclear if it contributes to the development of NAFLD through affecting dietary pattern. AIM: To examine the association among PNPLA3 gene polymorphism, dietary pattern, metabolic factors and NAFLD.
METHODS: Liver fat and fibrosis were assessed by proton-magnetic resonance spectroscopy and transient elastography in 920 subjects from a population screening project (251 had NAFLD). Dietary nutrient intake was recorded using a locally validated food-frequency questionnaire.
RESULTS: The prevalence of GG genotype in NAFLD subjects was 20.7%, compared to 10.6% in controls (P < 0.001). Macronutrient intake was similar among subjects with different PNPLA3 genotypes. The presence of G allele was a predictor of NAFLD independent of nutrient intake and other metabolic factors (adjusted odds ratio to CC: CG, 2.00; GG, 2.68). In subjects without metabolic syndrome, G allele was even more closely correlated with NAFLD diagnosis (adjusted odds ratio to CC: CG, 2.22; GG, 3.39). The prevalence of NAFLD was only 12% in subjects with CC genotype and no metabolic syndrome, and increased to 34% in those with GG genotype and no metabolic syndrome. While NAFLD subjects had significantly lower fibre intake, there was no significant interaction between PNPLA3 and dietary pattern.
CONCLUSIONS: The G allele in PNPLA3 rs738409 increases the risk of NAFLD in the general population, especially in subjects without metabolic syndrome, independent of dietary pattern and metabolic factors.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24417250     DOI: 10.1111/apt.12609

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  33 in total

1.  Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet.

Authors:  L Stinton; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2014-04       Impact factor: 8.171

2.  Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis.

Authors:  Xiao-Dong Gai; Wei-Feng Wu
Journal:  Exp Ther Med       Date:  2017-08-18       Impact factor: 2.447

Review 3.  Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.

Authors:  Becky Ching-Yeung Yu; Deborah Kwok; Vincent Wai-Sun Wong
Journal:  J Clin Exp Hepatol       Date:  2019-02-07

4.  Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring.

Authors:  Michelle T Long; Ellen B Gurary; Joseph M Massaro; Jiantao Ma; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin; Rohit Loomba
Journal:  Liver Int       Date:  2018-09-25       Impact factor: 5.828

Review 5.  Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.

Authors:  Yoshihiro Kamada; Hirokazu Takahashi; Masahito Shimizu; Takumi Kawaguchi; Yoshio Sumida; Hideki Fujii; Yuya Seko; Shinya Fukunishi; Katsutoshi Tokushige; Atsushi Nakajima; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2021-10-31       Impact factor: 7.527

6.  Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.

Authors:  Alexandra Feldman; Sebastian K Eder; Thomas K Felder; Lyudmyla Kedenko; Bernhard Paulweber; Andreas Stadlmayr; Ursula Huber-Schönauer; David Niederseer; Felix Stickel; Simon Auer; Elisabeth Haschke-Becher; Wolfgang Patsch; Christian Datz; Elmar Aigner
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

7.  Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.

Authors:  Jeremy Lok Wei; Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Grace Lai-Hung Wong; David Ka-Wai Yeung; Ruth Suk-Mei Chan; Henry Lik-Yuen Chan; Angel Mei-Ling Chim; Jean Woo; Winnie Chiu-Wing Chu; Vincent Wai-Sun Wong
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

Review 8.  Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals.

Authors:  Meaghan Phipps; Julia Wattacheril
Journal:  Frontline Gastroenterol       Date:  2019-12-13

9.  Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.

Authors:  Donghee Kim; Won Kim; Sae Kyung Joo; Jimin Han; Jung Ho Kim; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  J Gastroenterol       Date:  2019-09-18       Impact factor: 7.527

10.  PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity.

Authors:  Roshonda B Jones; Lide Arenaza; Claudia Rios; Jasmine F Plows; Paige K Berger; Tanya L Alderete; Jennifer L Fogel; Krishna Nayak; Passant Mohamed; Darryl Hwang; Suzanne Palmer; Frank Sinatra; Hooman Allayee; Rohit Kohli; Michael I Goran
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.